Last reviewed · How we verify
Anginin (PYRICARBATE)
Anginin (generic name: PYRICARBATE) is a pyricarbate drug. It is currently in Phase 2 development.
Anginin (PYRICARBATE) is thought to work by modulating a specific biological pathway, although the exact mechanism is not well understood.
Anginin (PYRICARBATE) is a small molecule drug in the pyricarbate class, but details about its development, approval status, and commercial availability are not available. As a result, there is limited information about its target, approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the clinical applications and safety profile of Anginin. The commercial status of Anginin is also unclear, making it difficult to determine if it is patented or available as a generic product. Overall, Anginin remains a relatively unknown compound in the pharmaceutical industry.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PYRICARBATE |
|---|---|
| Drug class | pyricarbate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a complex communication system. Anginin is believed to interact with this system, influencing how cells respond to certain signals. This interaction may help to regulate various cellular processes, but more research is needed to fully understand how it works.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anginin CI brief — competitive landscape report
- Anginin updates RSS · CI watch RSS
Frequently asked questions about Anginin
What is Anginin?
How does Anginin work?
What is the generic name of Anginin?
What drug class is Anginin in?
What development phase is Anginin in?
Related
- Drug class: All pyricarbate drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing